<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/1AC96B91-E629-4A7E-B45D-53507C6B8D6D"><gtr:id>1AC96B91-E629-4A7E-B45D-53507C6B8D6D</gtr:id><gtr:name>Acidophil Ltd.</gtr:name><gtr:address><gtr:line1>Station Rd,Salisbury Villas</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB1 2LA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1AC96B91-E629-4A7E-B45D-53507C6B8D6D" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>1AC96B91-E629-4A7E-B45D-53507C6B8D6D</gtr:id><gtr:name>Acidophil Ltd.</gtr:name><gtr:address><gtr:line1>Station Rd,Salisbury Villas</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB1 2LA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>210421.0</gtr:offerGrant><gtr:projectCost>300602.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/661AF1E2-FCA5-4C77-B00D-6360E9AF457A" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>661AF1E2-FCA5-4C77-B00D-6360E9AF457A</gtr:id><gtr:name>IsomeraSE Therapeutics Limited</gtr:name><gtr:address><gtr:line1>SUITE 9 SCIENCE VILLAGE , CHESTERFORD RESEARCH PARK</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB10 1XL</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>120032.0</gtr:offerGrant><gtr:projectCost>171474.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5EE7FC59-4D8D-4BC4-80A1-774C7877FE6C"><gtr:id>5EE7FC59-4D8D-4BC4-80A1-774C7877FE6C</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Aspland</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=103424"><gtr:id>6BDBAFA7-0001-4CE0-B24B-247C0ED19478</gtr:id><gtr:title>Natural product derived parasiticides for the protection of food animals</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>103424</gtr:grantReference><gtr:abstractText>Every year the loss of valuable livestock to invertebrate parasites, both endoparasites (nematodes or helminths) and ectoparasites (flies, ticks, mites and sea lice) totals &amp;gt;&amp;pound;34 billion globally. This is despite the fact that farmers spend ~&amp;pound;4.5 billion globally on parasiticides (compounds to treat parasitic infections). New products are continually needed as new parasites emerge and existing parasites evolve resistance. To compound this issue fewer novel agents are entering the market due to the increasing difficulties of discovering novel compounds and getting regulatory approval. In this project, Acidophil collaborating with Isomerase aim to combine synthetic biology and chemistry to generate novel natural product derived parasiticides to address the pressing unmet need in food animal health for new and cost effective parasiticides</gtr:abstractText><gtr:fund><gtr:end>2018-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2017-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>330453</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">103424</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>